Reject conventional cancer treatment; pursue alternative medicine only (no surgery, chemo, radiation, or hormone therapy)Accept conventional cancer treatment (surgery, chemotherapy, radiation, hormone therapy as indicated by stage)
Among 449 young breast cancer survivors, 25.2% regretted inactions
specifically — not seeking information sooner, not getting second opinions,
not being more proactive about their own care (Friedman et al. 2011). That
figure is the inaction-specific rate: 42.5% of the sample expressed any
regret, and of those, 59.2% pointed to inactions (42.5% × 59.2% = 25.2%).
Brewer et al.’s meta-analysis of 81 studies (N = 45,618) across vaccination,
screening, and other health domains confirmed the direction: anticipated
inaction regret correlated with actual health behavior at r = 0.29 and with
intentions at r = 0.50.
On the action side, a meta-analysis of 14 studies covering 17,883 localized
prostate cancer patients found that 20% reported significant decision
regret about their treatment choice, measured with the validated Decision
Regret Scale (Matta et al. 2023). The regret clusters around side effects —
sexual dysfunction, urinary incontinence, bowel problems — that follow
aggressive treatment of cancers that may never have become life-threatening.
Active surveillance patients reported the lowest regret (13%), while surgery
and radiotherapy patients hovered near 18–19%. A separate 15-year follow-up
of 934 men in the population-based Prostate Cancer Outcomes Study put the
overall figure at 14.6% (Hoffman et al. 2017). This is the best-quantified
cost of early diagnosis: roughly one in five to one in seven patients wish,
in retrospect, they had chosen differently.
The gap is narrower than it first appears. Prostate cancer screening is the
single most contested domain in the overdiagnosis debate — roughly 60% of
PSA-detected cancers may be overdiagnosed — so the 20% action-regret
figure is arguably an upper bound for early diagnosis in general. The
corrected inaction-specific rate (25.2%, not the previously stated 42.5%)
comes from a sample of young women with an aggressive cancer subtype, where
the consequences of delay are stark and visible. The revised delta (-0.052)
indicates a slight tilt toward inaction regret rather than a dramatic 2:1
ratio. For genuinely indolent conditions detected only by screening, the
calculus may reverse entirely. The directional finding — that health
inaction generates more long-term regret than health action — is supported
across the literature, but the magnitude depends heavily on what you are
being screened for and how likely the disease is to matter.
Sources: action
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]European Urology Open Science — Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis
Peer-reviewed
Pooled 20% (95% CI 16–23%) of patients reported significant decision regret across 14 studies
Excerpt
“"Significant decision regret was present in a pooled 20% (95% confidence interval 16–23) of patients across 14 studies and 17,883 patients. Regret was lower in active surveillance (13%), with little difference between radiotherapy (19%) and prostatectomy (18%)."
”
Source data from
2023-03-01
Accessed
2026-04-26
Calculation
Matta et al. 2023 meta-analysis of 14 studies using the Decision Regret Scale. The 20% pooled estimate captures regret from overdiagnosis, overtreatment, and side effects (sexual dysfunction, urinary incontinence) following early detection via PSA screening. Used as proxy for the broader cost of early diagnosis and aggressive treatment.
[2]Journal of Clinical Oncology — Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study
Peer-reviewed
14.6% expressed treatment decision regret at 15 years
Excerpt
“"Overall, 14.6% expressed treatment decision regret: 8.2% of those whose disease was managed conservatively, 15.0% of those who received surgery, and 16.6% of those who underwent radiotherapy."
”
Source data from
2017-07-12
Accessed
2026-04-26
Calculation
Hoffman et al. 2017. Prostate Cancer Outcomes Study, population-based cohort of 934 men followed for 15 years. The 14.6% overall figure is lower than the meta-analytic pooled 20%, likely because the longer follow-up selects survivors who have had time to rationalize their decision.
Sources: inaction
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]Psycho-Oncology / PMC — Post-Treatment Regret Among Young Breast Cancer Survivors
Peer-reviewed
42.5% of 449 young breast cancer survivors expressed regret; of those, 59.2% regretted inactions
Excerpt
“"The majority (59.2%) of participants who expressed regret did so over inactions ('I wish I had…', 'I would have…') as opposed to actions. Many women wished they had been more proactive in their care with respect to seeking information and having a better understanding of long-term effects and side effects of their treatment options."
”
Source data from
2011-01-01
Accessed
2026-04-26
Calculation
Friedman et al. 2011. Study of 449 young breast cancer survivors. 42.5% (191 of 449) expressed any regret. Of those who expressed regret, 59.2% regretted inactions (delayed screening, not seeking information sooner) rather than actions. Inaction-specific rate: 42.5% × 59.2% = 25.2% of the full sample regretted inactions. The prior entry incorrectly used 42.5% (total regret) as the inaction rate; the correct inaction-specific figure is 25.2%.
[2]Health Psychology — Anticipated Regret and Health Behavior: A Meta-Analysis
Peer-reviewed
Anticipated inaction regret predicted health behavior (r = 0.29, p < .001) and intentions (r = 0.50) across 81 studies
Excerpt
“"Greater anticipated regret from not engaging in a behavior (i.e., inaction regret) predicted stronger intentions and behavior. Anticipated inaction regret has a stronger and more stable association with health behavior than previously thought."
”
Source data from
2016-09-01
Accessed
2026-04-26
Calculation
Brewer et al. 2016 meta-analysis of 81 studies (N = 45,618). Demonstrates that across vaccination, screening, and other health domains, anticipated inaction regret consistently exceeds action regret. The correlation with actual health behavior is r = 0.29 (not r = 0.50, which is the correlation with intentions). The r = 0.29 figure is the relevant behavioral predictor; r = 0.50 applies to intention formation only. Both are statistically significant (p < .001).
Caveats
The action and inaction figures come from different clinical populations: a meta-analysis of localized prostate cancer patients (mostly older men) versus a study of young breast cancer survivors. The 20% action-regret figure is specific to treatment-decision regret after PSA-detected cancer — it likely overstates regret for early diagnosis in general, since prostate cancer screening is the most contested area of the overdiagnosis debate. The inaction- specific rate (25.2%) is derived from Friedman et al.: 42.5% of the sample expressed any regret, and 59.2% of those regrets were over inactions (42.5% × 59.2% = 25.2%). The prior entry incorrectly used the total 42.5% as the inaction rate. The Brewer meta-analysis shows anticipated inaction regret correlates with actual health behavior at r = 0.29 (not r = 0.50, which is the intentions correlation), providing converging evidence that the direction is robust across health behaviors. The revised delta (−0.052) suggests the gap between action and inaction regret is narrower than previously stated — early diagnosis carries meaningful regret costs (overtreatment side effects) that partially offset inaction regret. People with genuinely indolent conditions — detected only because of screening — may experience net harm from early diagnosis with no corresponding inaction-regret counterfactual.
